UV-1 is under clinical development by Ultimovacs and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how UV-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UV-1 is under development for the treatment of unresectable or metastatic malignant pleural melanoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, mesothelioma, recurrent head and neck cancer squamous cell carcinoma, hormone-sensitive metastatic prostate cancer and non small cell lung cancer. It is a synthetic peptide vaccine. The vaccine candidate is administered through intradermal and subcutaneous route. It consists of a mix of peptides which are fragments of the enzyme telomerase expressed by cancer cells allowing them to divide endlessly.
Ultimovacs is a pharmaceutical company that develops novel immunotherapies to treat cancer. The company offers product candidate UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. Its UV1 product candidate has being developed as a therapeutic cancer vaccine (TCV) for use as monotherapy. The company develops synthetic peptide-based therapeutic vaccines for therapies such as surgery, irradiation, and chemotherapy. It undertakes clinical trials to develop new products. Ultimovacs is headquartered in Oslo, Norway.
For a complete picture of UV-1’s drug-specific PTSR and LoA scores, buy the report here.